it's a trend that will continue, but they are good and have had no positive effect on price so far. Some insider buying could turn the pciture around, but good luck with that.
selling the puts on dips and calls against long stock on rallies has been working since VOL/prices are high and the stock is not moving much.
she made almost nothing on one of the sales 6.16 strike price and a year remaining, that's just rude and disrespectful to the shareholders. We need the insiders to start buying and stop selling, it's getting real OLD! I will remind the investors when it's time to vote again.
More insider selling. One block of options was about to expire, the other has another year to go and an exercise price of 6.16, are you kidding me. That's not a plus for shareholder confidence, she needs to be voted OUT on the next vote!
We have to give the dog some credit, it's no longer a reliable contra-indicator. Have you been going to doggy school? Very well timed on both the sell and the buy my furry friend.
Cramer and AF, both responsible for crimes against biotech companies IMO. Shorts probably bought several million shares yesterday and are selling some of them today to break long's spirit. Ignore them!
likely you are missing an education, a real job, maybe small portions of brain function, especially the part that is responsible for honesty and likely a few teeth. Did I miss anything? Now go and do something respectable with your life/time.
One month (not annual) range is 16.81-11.78, mid-point is 14.3. This might be great for ST traders, but not for LT shareholders. We need some news regarding progress in HUMANS, not mice and models.
Found some additional info on the upgrade. This looks encouraging and is what longs were all expecting, eventual replacement of Herceptin and a big sales number. If Roche thinks sales could reach $7BB, they should buy IMGN NOW.
cut and pasted: In the report, Canaccord Genuity noted, “We are initiating coverage of ImmunoGen with a BUY rating and $20 price target. We expect positive Phase 3 data for Kadcyla in HER2+ metastatic breast cancer, which could eliminate the need for chemotherapy in this setting. Kadcyla targets a $7B market opportunity long term, with royalties to ImmunoGen. ImmunoGen is also advancing its wholly-owned products.”
all 3 of the early stage drugs appear interesting, but they can't seem to get past the starting gate. The B-Cell drugs are very highly coveted. IMGN could go up $1B in value with some decent Phase I/II efficacy results. 289 was highly pumped by DJ, it's a bit too early to expect anything until at least year end, probably longer out based on their historic lack of speed. AMGN drugs should be close to reporting something. Sanofi MAb looks very interesting, not sure about the ADC. I am not even dreaming about $20+ this year.
yes, he's a broken record. I am negative on DJ and their development failures/lack of progress, but admire/appreciate the technology and John Lambert's drug discovery team and capability.
*DJ ImmunoGen Started at Buy by Canaccord Genuity
I hope they know something I don't about progress with the internal pipeline in HUMAN CLINICAL TRIALS. They have reported nothing of any significance in years. Where would IMGN be without Roche investing in and leading the development of TDM-1. John Lambert's team discovers the drugs, DJ gets everyone all excited about mouse models and then nothing ever happens. DJ must go! O'Leary must go! Fire these do-nothing dopes and hire someone that can move the internal drug portfolio forward in Humans, not mice.
or buy his #$%$, conflicted reports or services. Avoid, don't buy. FYI, the minute AF came out with an article dancing on the graves of biotech longs, the market turned yesterday. He is on a long run of bad calls and bad timing.
Cramer always says sell when ppl ask about ARNA, so any long with common sense would stop asking!!! A smart short will keep asking, knowing what he will say. Hello!
Were you the poster that said approval was a no-brainer, guaranteed, etc. Your posts remind me of a great saying, "better to be silent and thought the fool than to speak and remove all doubt."
You obviously have no idea what you are doing in biotech investing, so read a learn, which reminds me of another great saying, God gave us 2 ears and 1 mouth for a reason (listen 2x talking). The trial will take 2 years, they probably have just a few patients enrolled at this point and no one knows who gets drug and who gets placebo (I am assuming it's blinded).
good point, the shirt criminals do look for sentiment. After throwing up at lunch we are slightly relieved, but not ready to go shopping, or out to dinner.